Get regular updates to your inbox.
A noninvasive heart imaging scan may help identify cardiac sarcoidosis patients at risk of worse clinical outcomes, according to a study. A value of 42% or lower in left ventricular ejection fraction, or LVEF, a measure of how much blood is being pumped out of the heart’s left ventricle…
The Foundation for Sarcoidosis Research (FSR) has awarded $100,000 in funding to support U.S.-based research projects aimed at improving knowledge and diagnosis of cardiac sarcoidosis, a type of sarcoidosis that affects the heart. The funds were split into two cardiac sarcoidosis-specific grants, of $50,000 each. One…
Acthar Gel (repository corticotropin injection) may be a cost-effective approach relative to standard-of-care glucocorticoid therapy for adults with advanced active pulmonary sarcoidosis. That’s according to an analysis done by the therapy’s developer Mallinckrodt Pharmaceuticals, which found that “the initial high cost of Acthar Gel treatment for sarcoidosis…
Blood levels of the angiotensin-converting enzyme (ACE) — a common sarcoidosis biomarker — were able to distinguish between newly diagnosed sarcoidosis patients with single versus multiple organ involvement, a study shows. Also, higher blood levels of interleukin-2 receptor (IL-2R), an inflammatory marker, were linked with multiple organ involvement. ACE…
In Finland, only 2% of sarcoidosis patients without symptoms of eye involvement indeed had ocular sarcoidosis, suggesting that routine eye examinations are not needed in the Finnish patient population. But as the frequency of ocular sarcoidosis varies considerably among people with sarcoidosis worldwide, “more studies are needed to…
The European Medicines Agency (EMA) has granted XTMAB-16, Xentria‘s investigational antibody therapy, orphan drug designation for sarcoidosis. The status is intended to help speed the development of therapies that would fulfill an unmet health need for people with life-threatening or chronically debilitating rare diseases, which are defined as…
EFZO-FIT, a Phase 3 trial that’s testing treatment candidate efzofitimod in people with pulmonary sarcoidosis, is continuing  following a pre-planned interim safety review, with enrollment expected to finish in the first half of 2024. A data safety and monitoring board (DSMB) examined the trial’s available safety and tolerability…
The prognosis for people with cardiac sarcoidosis may depend on the condition of their heart at diagnosis and not on whether other organs are also affected, a study in Japan suggests. Isolated cardiac sarcoidosis, where the disease is limited to the heart, is a significant risk factor for worse…
For a young man in Belgium, a month-long headache combined with slurred speech and walking difficulties were the result of neurosarcoidosis, or sarcoidosis affecting the nervous system, a case study shows. The man’s neurosarcoidosis was part of a widespread form of sarcoidosis affecting multiple other organs, including the…
Workplace exposure to silica, mold/mildew, and pesticides were associated with an increased risk of pulmonary sarcoidosis in a recent review study. By analyzing data from dozens of published studies, scientists identified more than 80 different airborne factors that have been linked to the disease in at least one study.
Get regular updates to your inbox.